This week CNBC released its annual Disruptor 50 list of private companies that are revolutionizing their industries with innovative technology. After all, sometimes a company will have something that is so cutting edge that it will impact the entire direction of where a sector could be heading.
Finding the next big privately held company has also been something Jim Cramer is passionate about, which is why "Mad Money" frequently has its Off the Tape segment to highlight up and coming private companies.
Intarcia Therapeutics made its debut on CNBC's Disruptor list as No. 29. It is a biotech company that is committed to finding a better way to treat diabetes. Recent research indicates that less than half of those on medication for Type 2 diabetes stay on those drugs for an entire year, which can cause complications.
This length of time can often deter patients from taking their medication on a regular basis, or even at all, which will cease the drug from being effective. To find a solution to this problem, Intarcia developed a two-inch rod that is implanted under the patient's skin to deliver a slow, steady dose of a major Type 2 diabetes drug, Extenatide.